{"id":"W4283803757","doi":"10.15252/emmm.202115230","title":"Clinical grade ACE2 as a universal agent to block SARS‐CoV‐2 variants","year":2022,"lang":"en","type":"article","venue":"EMBO Molecular Medicine","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"National Institute of Allergy and Infectious Diseases; National Science Foundation; Canadian Institutes of Health Research; Innovative Medicines Initiative; Austrian Science Fund; European Commission; Österreichischen Akademie der Wissenschaften; National Cancer Institute; European Federation of Pharmaceutical Industries and Associations; U.S. Department of Health and Human Services; National Institutes of Health; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Center for Strategic Scientific Initiatives, National Cancer Institute","keywords":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Recombinant DNA; Potency; Coronavirus disease 2019 (COVID-19); Virology; Antibody; Neutralizing antibody; 2019-20 coronavirus outbreak; Chemistry; Microbiology; Biology; Molecular biology; Immunology; Virus; Medicine; Gene; Biochemistry; In vitro","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002952827,0.0003697722,0.0002856974,0.0001772663,0.0001136978,0.0003447473,0.0002635218,0.0003647321,0.002237836],"category_scores_gemma":[0.000169707,0.0001170104,0.0002037546,0.0001177486,0.0001911998,0.0002074388,0.0001792008,0.000793196,0.0004743942],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002275685,"about_ca_system_score_gemma":0.0002931198,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004344292,"about_ca_topic_score_gemma":0.001435126,"domain_scores_codex":[0.9998633,0.00002991639,0.000008552155,0.0000227358,0.00003892864,0.00003655417],"domain_scores_gemma":[0.999933,0.00001063875,0.00001416657,0.000009253023,0.00001312814,0.00001980572],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.000400811,0.0004089808,0.0002717201,0.0001211164,0.00002312135,0.0001380518,0.00002716968,0.0002936375,0.9835215,0.0003695668,0.0007154092,0.0137089],"study_design_scores_gemma":[0.000415837,0.005815552,0.002642907,0.00002706139,0.00005030287,0.001173998,0.00003557994,0.001488822,0.9705839,0.0001227185,0.01763299,0.00001026561],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9618547,0.0109171,0.01287133,0.0007552884,0.0002684026,0.000436571,0.000621941,0.0002833418,0.01199122],"genre_scores_gemma":[0.9821438,0.003936193,0.006455664,0.0002917025,0.00006659893,0.00009119903,0.0009474983,0.00002241528,0.006044963],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002237836,"threshold_uncertainty_score":0.007486284,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06518186342974834,"score_gpt":0.4089792007146749,"score_spread":0.3437973372849265,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}